← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Net income decreased 16.5% to ($103.7M), while Operating cash flow increased 3.9% to ($70.3M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AWatch
- Profitability — Net income ($103.7M)Watch
- Cash generation — Free cash flow ($70.5M)Note
- Accounting — No applicable forensic screenNote
- Insiders — 0 buys; 38 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Business
Enliven Therapeutics, Inc.: By combining clinically validated targets and specific target product profiles with disciplined clinical trial design and regulatory strategy, we aim to develop drugs that address unmet needs with an increased probability of clinical and commercial success.
Leadership changes
From Enliven Therapeutics, Inc.'s own filings, the day they're filed.
- Scott Garland · director · appointmenteff. 2026-01-07
- Andrew Phillips · director · departureeff. 2026-01-06
- Samuel Kintz · Chief Executive Officer · appointmenteff. 2025-12-11
Latest filings
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-06-12
- 8-K · Company announcement2026-06-11
- 8-K · Company announcement2026-06-10
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Enliven Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.